During the last session, Odonate Therapeutics, Inc. (NASDAQ:ODT)’s traded shares were 148,000,000, with the beta value of the company hitting 0. At the end of the trading day, the stock’s price was $3.88, reflecting an intraday gain of 12.14% or $0.42. The 52-week high for the ODT share is $46.5, that puts it down -1098.45% from that peak though still a striking +22.16% gain since the share price plummeted to a 52-week low of $3.02. The company’s market capitalization is $149.78 Million, and the average intraday trading volume over the past 10 days was 1.62 Million shares, and the average trade volume was 1.36 Million shares over the past three months.
Odonate Therapeutics, Inc. (ODT) received a consensus recommendation of Underweight from analysts. That translates to a mean rating of 3.2. ODT has a Sell rating from 1 analyst(s) out of 4 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and no one recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.81.
Odonate Therapeutics, Inc. (NASDAQ:ODT): Trading Information
Odonate Therapeutics, Inc. (ODT) registered a 12.14% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 21.93% in intraday trading to $4.97- this Wednesday, Apr 07, hitting a weekly high. The stock’s 5-day price performance is 21.63%, and it has moved by -78.07% in 30 days. Based on these gigs, the overall price performance for the year is -79.79%. The short interest in Odonate Therapeutics, Inc. (NASDAQ:ODT) is 2.67 Million shares and it means that shorts have 1.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $4, which implies an increase of 3.09% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $4 respectively. As a result, ODT is trading at a discount of 3.09% off the target high and 3.09% off the low.
Odonate Therapeutics, Inc. (ODT) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return 5% in 2021, the next five years will return 0% per annum.
Odonate Therapeutics, Inc. (NASDAQ:ODT)’s Biggest Investors
Odonate Therapeutics, Inc. insiders own 3.51% of total outstanding shares while institutional holders control 105.8%, with the float percentage being 109.65%. Tang Capital Management, LLC is the largest shareholder of the company, while 156 institutions own stock in it. As of Dec 30, 2020, the company held over 15.51 Million shares (or 40.19% of all shares), a total value of $297.88 Million in shares.
The next largest institutional holding, with 5.61 Million shares, is of Boxer Capital, LLC’s that is approximately 14.52% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $107.66 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also, the Mutual Funds coming in first place with the largest holdings of Odonate Therapeutics, Inc. (ODT) shares are Janus Henderson Global Life Sciences Fund and Vanguard Total Stock Market Index Fund. Data provided on Dec 30, 2020 indicates that Janus Henderson Global Life Sciences Fund owns about 936,474 shares. This amounts to just over 2.43 percent of the company’s overall shares, with a $17.98 Million market value. The same data shows that the other fund manager holds slightly less at 449.65 Thousand, or about 1.16% of the stock, which is worth about $8.63 Million.